Neoadjuvant therapy (NAT) has become an adapt therapy for patients with inoperable as well as some high-risk breast cancer, such as stage II–III HER-2 positive (HER2+) and triple-negative breast cancer (TNBC) (1, 2). The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.